NASDAQ$DERM
Journey Medical Corp · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Announced financial results for Q4 and full year ended December 31, 2022.
Journey Medical reported its Q4 and full year 2022 financial results, highlighting revenue growth for Qbrexza and Accutane, along with contributions from Amzeeq and Zilxi, which accounted for approximately 77% of the total revenue for the year.
- Generated record total revenues of $73.7 million for the full year 2022
- Completed enrollment in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea; topline data are expected in the first half of 2023
- Observed revenue growth for Qbrexza® and Accutane®
- Amzeeq® and Zilxi® contributed to revenue after being acquired in January 2022
Headline financials
Revenue & EPS history
Journey Medical · Revenue · Quarterly
$16M
Forward guidance
Journey Medical anticipates continued revenue growth from key products and achieving clinical milestones in Phase 3 clinical trials evaluating DFD-29 for rosacea.
Tailwinds
- Continued revenue growth from key products
- Top-line data read out from the DFD-29 Phase 3 clinical trials in the second quarter of 2023
- File a New Drug Application (“NDA”) in the second half of 2023
- Focus on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products
- Efficient sales and marketing model
Headwinds
- Impact of generic competition on Targadox® brand
- Supply chain issues for Ximino® and Exelderm®
- Risks relating to growth strategy
- Dependence on third-party suppliers
- Potential recovery of funds lost from previously disclosed cyber security breaches
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2022
-2.9%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+5.1%
Avg return
30 days after
39%
9 / 23 earnings
Positive
+22.0%
Q1 2025
Best reaction
-26.8%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -26.8% | -1.1% | — | |
| Q1 2026 | +3.0% | +24.4% | +26.5% | |
| Q3 2025 | -15.3% | -12.4% | -15.5% | |
| Q2 2025 | -15.1% | -18.0% | -16.7% | |
| Q1 2025 | +22.0% | +15.2% | +13.6% | |
| Q4 2024 | -3.6% | -2.8% | +21.7% | |
| Q3 2024 | -8.2% | -7.5% | -9.3% | |
| Q2 2024 | -3.2% | -11.0% | -3.8% | |
| Q1 2024 | +2.8% | -1.7% | +69.2% | |
| Q4 2023 | -14.1% | -3.9% | -9.4% | |
| Q3 2023 | +15.7% | +14.8% | +105.5% | |
| Q2 2023 | +14.0% | +4.7% | +21.5% | |
| Q1 2023 | -10.1% | -23.2% | +44.9% | |
| Q4 2022 | +3.1% | +13.1% | +26.3% | |
| Q3 2022 | -8.7% | -9.2% | -27.2% | |
| Q2 2021 | -4.3% | -7.0% | -30.1% | |
| Q2 2022 | -4.3% | -7.0% | -30.1% | |
| Q1 2022 | -12.3% | +5.1% | +0.8% | |
| Q1 2021 | -12.3% | +5.1% | +0.8% | |
| Q4 2021 | +5.4% | +6.1% | -1.8% | |
| Q3 2020 | +3.4% | -0.1% | -24.3% | |
| Q4 2020 | +3.4% | -0.1% | -24.3% | |
| Q3 2021 | +0.0% | +0.0% | -25.5% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro